Category Press Releases

2025 Gynecology Licensing Trends Report: 150+ Deals by Company, Therapy & Tech

Comprehensive Report Reveals Key Trends in Gynecology Collaboration and Licensing Deals from 2016 to 2025 Gynecology Collaboration and Licensing Deals report offers a deep dive into the evolving landscape of partnerships in women’s health, providing unparalleled insights into over 150…

Read More2025 Gynecology Licensing Trends Report: 150+ Deals by Company, Therapy & Tech

Dyadic International Rebrands as Dyadic Applied BioSolutions

Dyadic International Rebrands as Dyadic Applied BioSolutions, Marking Strategic Shift Toward Commercial Bioprocessing Solutions Dyadic International, Inc. (Nasdaq: DYAI), a global biotechnology company known for its proprietary gene expression platforms, has announced a strategic rebrand that reflects its evolution from…

Read MoreDyadic International Rebrands as Dyadic Applied BioSolutions

Sunshine Biopharma Launches NIOPEG® into $10B Biologics Market

Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of…

Read MoreSunshine Biopharma Launches NIOPEG® into $10B Biologics Market

Pneumagen Publishes Positive Phase II Data for Broad-Spectrum Antiviral Neumifil

Pneumagen Publishes Promising Phase II Results of Neumifil in Peer-Reviewed Journal, Demonstrating Potential as Broad-Spectrum Antiviral for Respiratory Infections Pneumagen, a clinical-stage biotechnology company focused on developing broad-spectrum antivirals, announced the peer-reviewed publication of its positive Phase II clinical trial…

Read MorePneumagen Publishes Positive Phase II Data for Broad-Spectrum Antiviral Neumifil

Alume Biosciences Publishes First-in-Human Bevonescein Nerve Imaging Data in Nature Communications

Alume Biosciences Publishes First-in-Human Data on Bevonescein for Nerve Imaging in Nature Communications Alume Biosciences, a late-clinical stage biotechnology company focused on improving surgical safety through nerve-illuminating technologies, has announced the publication of first-in-human clinical data for its lead compound,…

Read MoreAlume Biosciences Publishes First-in-Human Bevonescein Nerve Imaging Data in Nature Communications

Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention

Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan.…

Read MoreAsahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention